Journalist based in NYC. Bylines @ CNBC, International Business Times, World Policy Journal. (all views my own)
Earnings expectations are high for biotech industry leader Gilead Sciences Inc. Investors want to see that the company’s main source of its revenue — the demand for hepatitis C (HCV) drugs — is still strong.
How The Academy Misunderstood Robin Williams’ Suicide
